including 61 patients with mantle cell lymphoma (MCL) and 19 with Waldenström's macroglobulinemia (WM) who had previously been treated with a covalent BTK inhibitor. In MCL, the drug had an ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL ... Brukinsa is a bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that can cause cancer cells to grow.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The FDA has promised a fast review for Bayer's cancer drug, copanlisib, for a hard-to-treat lymphoma ... as Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) is proving popular with ...

“Our BTK inhibitor BRUKINSA has become a standard ... for R/R chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Updated results from a Phase 2 study of WM patients who ...

Studies of BRUKINSA ® (zanubrutinib), BTK CDAC degrader BGB-16673 and ... degrader BGB-16673 and B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in patients with Waldenström’s macroglobulinemia ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...